vs
Side-by-side financial comparison of HARTE HANKS INC (HHS) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $20.6M, roughly 1.9× Entrada Therapeutics, Inc.). HARTE HANKS INC runs the higher net margin — 5.5% vs -84.4%, a 89.9% gap on every dollar of revenue. On growth, HARTE HANKS INC posted the faster year-over-year revenue change (-15.4% vs -65.2%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -6.4%).
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
HHS vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $20.6M |
| Net Profit | $2.2M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -0.3% | -106.0% |
| Net Margin | 5.5% | -84.4% |
| Revenue YoY | -15.4% | -65.2% |
| Net Profit YoY | — | -173.8% |
| EPS (diluted) | $0.30 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $39.9M | — | ||
| Q3 25 | $39.5M | — | ||
| Q2 25 | $38.6M | — | ||
| Q1 25 | $41.6M | $20.6M | ||
| Q4 24 | $47.1M | $37.4M | ||
| Q3 24 | $47.6M | $19.6M | ||
| Q2 24 | $45.0M | $94.7M | ||
| Q1 24 | $45.4M | $59.1M |
| Q4 25 | $2.2M | — | ||
| Q3 25 | $-2.3M | — | ||
| Q2 25 | $-335.0K | — | ||
| Q1 25 | $-392.0K | $-17.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $142.0K | $-14.0M | ||
| Q2 24 | $-27.8M | $55.0M | ||
| Q1 24 | $-171.0K | $23.5M |
| Q4 25 | -0.3% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | -0.1% | -106.0% | ||
| Q4 24 | -3.3% | -15.7% | ||
| Q3 24 | 4.0% | -110.7% | ||
| Q2 24 | 3.0% | 56.4% | ||
| Q1 24 | 0.8% | 35.7% |
| Q4 25 | 5.5% | — | ||
| Q3 25 | -5.8% | — | ||
| Q2 25 | -0.9% | — | ||
| Q1 25 | -0.9% | -84.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | 0.3% | -71.7% | ||
| Q2 24 | -61.8% | 58.1% | ||
| Q1 24 | -0.4% | 39.7% |
| Q4 25 | $0.30 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $-0.05 | $-0.42 | ||
| Q4 24 | $-0.31 | $-0.20 | ||
| Q3 24 | $0.02 | $-0.35 | ||
| Q2 24 | $-3.84 | $1.55 | ||
| Q1 24 | $-0.02 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.6M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.5M | $417.3M |
| Total Assets | $91.8M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $9.0M | $67.8M | ||
| Q4 24 | $9.8M | $101.2M | ||
| Q3 24 | $5.9M | $78.0M | ||
| Q2 24 | $11.0M | $185.3M | ||
| Q1 24 | $11.5M | $68.4M |
| Q4 25 | $20.5M | — | ||
| Q3 25 | $19.9M | — | ||
| Q2 25 | $22.2M | — | ||
| Q1 25 | $21.4M | $417.3M | ||
| Q4 24 | $21.7M | $428.7M | ||
| Q3 24 | $21.0M | $422.4M | ||
| Q2 24 | $20.6M | $429.9M | ||
| Q1 24 | $20.0M | $269.4M |
| Q4 25 | $91.8M | — | ||
| Q3 25 | $92.7M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $100.6M | $486.5M | ||
| Q4 24 | $101.8M | $526.3M | ||
| Q3 24 | $108.1M | $554.6M | ||
| Q2 24 | $109.7M | $582.0M | ||
| Q1 24 | $113.4M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $737.0K | $-38.5M |
| Free Cash FlowOCF − Capex | $-686.0K | $-39.7M |
| FCF MarginFCF / Revenue | -1.7% | -192.9% |
| Capex IntensityCapex / Revenue | 3.6% | 5.6% |
| Cash ConversionOCF / Net Profit | 0.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.5M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $737.0K | — | ||
| Q3 25 | $3.2M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $-818.0K | $-38.5M | ||
| Q4 24 | $4.0M | $-31.6M | ||
| Q3 24 | $-2.9M | $-24.3M | ||
| Q2 24 | $1.6M | $39.8M | ||
| Q1 24 | $-5.7M | $-25.5M |
| Q4 25 | $-686.0K | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $-5.1M | — | ||
| Q1 25 | $-923.0K | $-39.7M | ||
| Q4 24 | $3.4M | $-32.2M | ||
| Q3 24 | $-4.9M | $-24.9M | ||
| Q2 24 | $926.0K | $38.8M | ||
| Q1 24 | $-6.2M | $-26.4M |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | -13.1% | — | ||
| Q1 25 | -2.2% | -192.9% | ||
| Q4 24 | 7.3% | -86.2% | ||
| Q3 24 | -10.2% | -127.3% | ||
| Q2 24 | 2.1% | 41.0% | ||
| Q1 24 | -13.7% | -44.6% |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | 5.6% | ||
| Q4 24 | 1.3% | 1.7% | ||
| Q3 24 | 4.0% | 3.3% | ||
| Q2 24 | 1.5% | 1.1% | ||
| Q1 24 | 1.2% | 1.4% |
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | -20.76× | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
TRDA
Segment breakdown not available.
